Cidara Therapeutics is a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing cancer and other serious diseases.

National Institutes of Health

CARB-X

Square 1 Bank

venBio Partners

Rock Springs Capital

Sabby Capital

5AM Ventures

Aisling Capital

RA Capital Management

Fidelity

Cidara Therapeutics

Today our treatment for adults with invasive candidiasis has been approved by the United Kingdom MHRA. Read here for more information on this milestone: https://brnw.ch/21wGuRc

In case you missed it, the European Commission approved our treatment for adults with invasive candidiasis, triggering an $11M milestone payment that we will use to continue the development of our Cloudbreak platform in oncology. Learn more about the approval: https://brnw.ch/21wFMcE

Today, we announced our treatment option for adults with invasive candidiasis has been approved in the European Union. Read more about this significant milestone for patients here: https://brnw.ch/21wFxOY

We’re excited to share we presented new preclinical data at the ESMO - European Society for Medical Oncology Immuno-Oncology Congress, demonstrating anti-tumor activity of our multi-specific CD73/PD-1 inhibitor drug-Fc conjugate (DFC) candidate. Read more: https://brnw.ch/21wF786 #ESMOImmuno23

SCYNEXIS is a biotechnology company specializing in the development of novel anti-infectives to address significant unmet therapeutic needs.

SCYNEXIS Inc

Baxter is a global healthcare company that develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.

Baxter

Astellas is a pharmaceutical company that focuses on the development of innovative therapies for various medical conditions, including infectious diseases and cancer.

Astellas

Cabaletta Bio is a biotechnology company that specializes in the development of T cell therapies for the treatment of B cell-mediated autoimmune diseases.

Cabaletta Bio

Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19.

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 7, 2024 10:46 PM	9a1b4cc1
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 10:46 PM	21aee3a2
company summary	general
signals	general	Mar 7, 2024 10:46 PM	050ad05b
crunchbase trigger	general	Nov 27, 2024 12:50 PM	d7a8956e
crunchbase profile	general
li profile	general	Mar 7, 2024 10:46 PM	b30efb74
translate crunchbase fundingrounds	general
peers	general	Mar 7, 2024 10:46 PM	a076954c
news basic	general	Mar 7, 2024 10:46 PM	1b7edef2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CIDARA

Cidara Therapeutics, Inc.

Last Close

17.45

22/11 21:00

Market Cap

51.64M

Beta: -

Volume Today

219.11K

Avg: -